Bivalent BA.4/5 Omicron subvariant vaccine / Novavax - LARVOL DELTA

Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines (clinicaltrials.gov) - P2/3 | N=994 | Completed | Sponsor: Novavax | Active, not recruiting ➔ Completed | Trial completion date: Nov 2024 ➔ May 2024

Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines (clinicaltrials.gov) - P2/3 | N=994 | Active, not recruiting | Sponsor: Novavax | N=1980 ➔ 994

Enrollment change • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines (clinicaltrials.gov) - P2/3 | N=1980 | Active, not recruiting | Sponsor: Novavax | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines (clinicaltrials.gov) - P2/3 | N=1980 | Recruiting | Sponsor: Novavax | Not yet recruiting ➔ Recruiting | Trial completion date: May 2024 ➔ Nov 2024

Enrollment open • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases